making new medical technologies available in Hungary

Boston Scientific receives CE mark for Eluvia™ drug-eluting vascular stent and announces initiation of new clinical trial

22 Feb 2016 First polymer-based, drug-eluting stent designed to treat peripheral lesions above the knee approved in Europe; IMPERIAL trial initiated to seek regulatory approvals in U.S. and Asia Boston Scientific, today announced that the Eluvia™ Drug-Eluting Vascular Stent System has received...
READ MORE

Tryton Medical Announces Publication of Post Hoc Analysis of Randomized Clinical Trial in Treatment of Bifurcation Lesions using Tryton Side Branch Stent

Analysis showed reductions in target vessel failure and improved side branch percent diameter stenosis in patients with a coronary bifurcation lesion in vessels 2.25mm in diameter or greater September 30, 2015 06:30 AM Eastern Daylight Time DURHAM, N.C.–(BUSINESS WIRE)–Tryton...
READ MORE

News Releases Eluvia™ Drug-eluting Vascular Stent System Demonstrates 12-month Primary Patency Of 96.1 Percent

MAJESTIC Trial Data Support Strong Safety Profile with Low Target Lesion Revascularization Rate Sep 28, 2015 MARLBOROUGH, Mass., Sept. 28, 2015 /PRNewswire/ — New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific (NYSE: B...
READ MORE

One-year outcomes in unselected patients treated with a thin-strut, platinum-chromium, paclitaxel-eluting stent: primary endpoint results from the TAXUS Element European post-approval surveillance study (TE-PROVE)

Corrado Tamburino1, MD, PhD; Davide Capodanno1*, MD, PhD; Andrejs Erglis2, MD; Ian B.A. Menown3, MD, FRCP; Iván G. Horváth4, MD, PhD; Raul Moreno5, MD; Timothy J. Gilbert6, MB, FRCP; James J. Crowley7, MD; Paolo Calabria8, MD; Dominic J. Allocco9, MD; Keith D. Dawkins9, MD 1. Ferrarotto...
READ MORE

Percutaneous left atrial appendage closure in patients with left atrial appendage thrombus

Felix Meincke, MD; Felix Kreidel, MD; Jasper von Wedel, MD; Ulrich Schäfer, MD; Karl-Heinz Kuck, MD; Martin W. Bergmann*, MD Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany This paper also includes accompanying supplementary data published online at:...
READ MORE

One-year outcomes in 1,010 unselected patients treated with the PROMUS Element everolimus-eluting stent: the multicentre PROMUS Element European Post-Approval Surveillance Study

Martyn R. Thomas1*, MD, PhD; Ralf Birkemeyer2, MD; Peter Schwimmbeck3, MD, PhD; Victor Legrand4, MD, PhD; Raul Moreno5, MD; Carlo Briguori6, MD; Nikos Werner7, MD; Ezio Bramucci8, MD; Imre Ungi9, MD; Gert Richardt10, MD, PhD; Paul L. Underwood11, MD; Keith D. Dawkins11, MD 1. Guy’s and St....
READ MORE

Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study

Horst Sievert1*, MD; Joachim Schofer2, MD; John Ormiston3, MBChB; Uta C. Hoppe4, MD; Ian T. Meredith5, MD; Darren L. Walters6, MD; Michel Azizi7,8, MD; Juan Diaz-Cartelle9, MD; Meital Cohen-Mazor9,10, PhD; on behalf of the REDUCE-HTN investigators 1. CardioVascular Center Frankfurt CVC,...
READ MORE

Vessix™ – Renal Denervation System

Study Design The REDUCE-HTN Post-Market Study (PMS), including the First in Man (FIM) cohort, is a prospective, non-randomized, single arm, multicenter study evaluating the Vessix™ Renal Denervation System in patients with resistant hypertension. Enrolled patients had office-based systolic...
READ MORE

SYNERGY Stent Investigator-Sponsored Research

The SYNERGY Stent Investigator-Sponsored Research1 Program will study the SYNERGY Stent in many different patient populations that interventional cardiologists see in their everyday practice. SYNERGY Stent Clinical Trials Supporting Research of the SYNERGY Stent Top 1Boston Scientific is not...
READ MORE